The Lynx Group
Cholangiocarcinoma News

August 2020, Vol 1, No 1

Varlitinib is a reversible small-molecule, pan human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.
Read More

In patients with locally advanced or metastatic biliary tract cancer, treatment with second-line chemotherapy is challenging after disease progression from first-line gemcitabine plus cisplatin, although treatment with modified FOLFOX (mFOLFOX) has been proven to be superior to active symptom control in the ABC-06 trial. Irinotecan (Camptosar) is an active drug used in the treatment of various gastrointestinal cancers.
Read More

Mutations in IDH1 are detected in approximately 13% of patients with intrahepatic cholangiocarcinoma (CCA). ClarIDHy was a global, phase 3, double-blind clinical trial in previously treated patients with advanced intrahepatic CCA with IDH1 mutation.
Read More

Genomic alterations that are characteristic of intrahepatic cholangiocarcinoma (CCA) are well known. A study led by Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, MA, examined whether genomic alterations from a primary tumor would differ from metastatic tumor tissue and liquid biopsy in patients with intrahepatic CCA. The study results were presented at the 2020 ASCO annual meeting.
Read More

Treatment with 6 months of adjuvant capecitabine chemotherapy is currently the standard of care in patients with resected extrahepatic cholangiocarcinoma (CCA). However, the benefit of treatment with adjuvant radiation therapy is not well-defined.
Read More

The 2020 Cholangiocarcinoma Foundation (CCF) Annual Conference was held virtually this year, as did all oncology conferences, because of the COVID-19 pandemic. More than 1400 people, including patients, caregivers, clinicians, researchers, and industry experts from 49 states and 42 countries, participated in the conference. This year, CCF invited patients and caregivers to share their experiences and concerns with fellow conference attendees.
Read More

Fred Koehl, who spoke at the 2020 Cholangiocarcinoma Foundation (CCF) Annual Conference, was a 62-year-old healthy man living in Atlanta, GA, who was “not ready to go” when he was diagnosed with extrahepatic cholangiocarcinoma (CCA) 7 years ago. Mr Koehl’s disease was diagnosed at an early stage (stage I), and after surgery to remove the tumor (including part of his pancreas), radiation, and 12 cycles of gemcitabine and cisplatin therapy, he was told he had “no evidence of disease.”
Read More

In fall 2016, Nina Petrow was a successful, healthy, 38-year-old woman living with her husband Randy Pike, in San Antonio, TX. She was a mom for the third time, having given birth to a son, Nikolas, just 5 weeks before receiving the devastating news on November 29 that she had stage IV cholangiocarcinoma (CCA).
Read More

During the 2020 Cholangiocarcinoma Foundation (CCF) Annual Conference, Melinda Bachini, Director of Advocacy for the foundation, presented an update on the foundation’s advocacy activities and initiatives toward promotion of the cholangiocarcinoma (CCA) community.
Read More

Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, and Co-Chair of the 2020 Cholangiocarcinoma Foundation Annual Conference, provided an update of important global clinical trial developments since the last conference of the foundation. Dr Shroff reminded the audience that the ABC-02 clinical trial established the use of gemcitabine and cisplatin chemotherapy as the standard of care for patients with metastatic or unresectable cholangiocarcinoma (CCA) since 2010.
Read More

Page 2 of 3

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: